相关实验视频
Updated: Jun 21, 2026
08:28
Development of an In Vitro Ocular Platform to Test Contact Lenses
Published on: April 6, 2016
11.2K
使用纳米结构脂质载体装载软接触镜片进行Epalrestat的增强眼部传递
Ketan Ranch1, Yashkumar Patel1,2, Esha Acharya1
1Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380009, Gujarat, India.
Pharmaceutics
|December 31, 2025
概括
这项研究开发了装入隐形眼镜的新型纳米结构脂质载体 (NLC),用于增强epalrestat (EPL) 输送,以治疗糖尿病视网膜病变. 装有NLC的隐形眼镜证明了眼部生物可用性和安全性的改善,提供了有前途的治疗进展.
科学领域:
- 眼科药物输送 眼科药物输送
- 纳米技术在制药中的应用
- 糖尿病视网膜病变治疗方法 治疗方法
背景情况:
- 埃帕雷斯塔特 (EPL) 具有较差的水溶性和有限的眼部生物可用性,阻碍了它对糖尿病视网膜病变的有效性.
- 纳米结构脂质载体 (NLCs) 为改善药物输送提供了一个潜在的解决方案.
- 隐形眼镜为持续的眼部药物释放提供了一个新的平台.
研究的目的:
- 为了开发和优化epalrestat载荷的NLCs.
- 将优化的NLC集成到隐形眼镜中,以增强眼部传递.
- 为了评估含有NLC的隐形眼镜的物理化学性质,药物释放,角膜透性和眼睛安全性.
主要方法:
- 使用Compritol® 888 ATO,LabrafacTM WL 1349和Solutol® HS 15通过高速同质化制备了装有EPL的NLC.
- 使用D-最佳混合物设计优化配方.
- 使用浸泡技术将优化的NLC纳入隐形眼镜中,并对各种参数进行评估.
主要成果:
- 优化的NLC表现出小球体大小 (41.85nm),高捕获效率 (93.32%) 和出色的物理稳定性.
- 带有NLC的隐形眼镜显示出足够的胀 (140.69%),透明度 (80.54%) 和药物含量 (96.32%).
- 观察到持续的体外药物释放 (98.12%在24小时内) 和显著增强的体外角膜透率 (97.26%在6小时). 在体内测试证实了生物相容性.
结论:
- 开发的epalrestat NLCs装载的隐形眼镜系统显著提高角膜透率,并延长药物保留时间.
- 这种新的系统为糖尿病视网膜病变管理提供了改善的眼部生物可用性和治疗疗效.
- 装有NLC的隐形眼镜显示出卓越的眼睛安全性,减少剂量频率并改善患者的遵守性.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...